|
|
|
Market Research Report
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases
|
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases published by Decision Resources, Inc. in October, 2009. This report consists of 32 Pages and the price starts from US $ 4600.
Abstract
Introduction
Biomarkers and imaging tools are enabling technologies in today' s clinical
research efforts for neurological diseases. Whether to improve upon existing
methods for monitoring disease progression or to discover validated measures
to detect diseases earlier than before, nearly every neurology trial is
relying on biomarkers and/or has an imaging component. Although some
biomarkers and imaging tools are better than others, companies in this market
that are aiming to unveil a truly unique or even a signifi cantly improved
therapy must incorporate biomarkers in their R&D strategies - it would be
foolish not to.
Get the Answers You Need to Shape Your Strategy
- The uses of biomarkers in neurology are varied - drug discovery,
monitoring disease progression/drug action, and diagnostic development - and
can depend on the indication. In what ways are biomarkers being explored in
Parkinson' s disease compared with Alzheimer' s disease? How has the use of
biomarkers aligned with an outcome measure for a study in ALS?
- Clearly defi ned biomarkers in the neurology therapeutic area are
missing. Are we close to discovering appropriate biomarkers for use in
diagnostic tests to detect diseases early enough to truly change the
therapeutic landscape in neurology?
- Imaging modalities are used frequently in neurological drug and diagnostic
research. How many industry- sponsored active studies are employing imaging
tools as their biomarker intervention? Which indication(s) relies on imaging
the most?
Scope
- High-interest neurological diseases: Alzheimer' s disease (AD),
amyotrophic lateral sclerosis (ALS), Huntington' s disease (HD), multiple
sclerosis (MS), and Parkinson' s disease (PD).
- Analysis of 117 biomarker-based clinical trials as of September
2009: Study type, phase in development, indication.
- A look at 75 biomarker/diagnostics-based deals across six years:
Company type (large-cap, midcap, small-cap), deal type, and
indication-specific.
Mentioned in This Spectrum Report
Companies
- Adlyfe
- Amgen
- Arrayit
- AstraZeneca
- Aventis Pharmaceuticals
- Avid Radiopharmaceuticals
- Axela
- Bayer Schering
- biOasis Technologies
- BioMerieux
- BioMS Medical
- Bionomics
- Bristol-Myers Squibb
- Celera
- Celera Diagnostics
- CogState
- Competitive Technologies
- deCode Genetics
- DiaGenic
- Eisai
- Eli Lilly
- Forest Laboratories
- GE Healthcare
- General Electric
- Genizon BioSciences
- GlaxoSmithKline
- Luminex
- Lundbeck
- Illumina
- Inverness Medical Innovations
- KineMed
- MDS Nordion
- Merck
- Merz Pharmaceuticals
- Millipore
- Myriad Genetics
- Neurochem
- Neuroptix
- Novartis
- Nymox
- Opko Health
- Pfi zer
- Proteome Sciences
- ProteoTech
- Quest Diagnostics
- RayBiotech
- Roche
- Roche Diagnostics
- Safeguard Scientifi cs
- Satoris
- Siemens Medical Solutions
- Solvay Pharmaceuticals
- Taisho Pharmaceutical
- Wyeth
- Xennex
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Diagnosing Neurological Diseases
- Diagnostic Imaging Applications
- Biomarkers in Clinical Trials
- Indication-Specifi c Biomarkers of Interest
- Alzheimer' s Disease and Mild Cognitive Impairment
- Multiple Sclerosis
- Parkinson' s Disease
- Amyotrophic Lateral Sclerosis
- Huntington' s Disease
- Biomarker and Diagnostic Neurology Deals
- Indication-Specifi c Deals
- Company-Specifi c Deals
- Outlook
Sidebar
- Commonly Used Imaging Technologies in Clinical Neurology
Expert Commentary
- “Value of Licensing Biomarkers of Alzheimer' s Disease”
- Q&A with Rainer Voegeli, Ph.D., Commercial Director at Proteome Sciences
Tables
- 1. Descriptions of Select Neurological Diseases
- 2. Top Five Currently Recruiting Clinical Trials in Neurology, Largest
Enrollment
- 3. Diagnostic Tests for Multiple Sclerosis
- 4. Inheritance Patterns of Huntington' s Disease
- 5. Biomarker and Diagnostic Neurology Deals in the First Half of 2009
- 6. Biomarker and Diagnostic Deals Involving Large-Cap Healthcare
Companies, 2004- First Half 2009
Figures
- 1. Biomarker-Based, Closed-Enrollment, Completed Neurology Clinical Trials
by Phase and Indication, September 2009
- 2. Biomarker-Based, Closed-Enrollment, Active Neurology Clinical Trials by
Phase and Indication, September 2009
- 3. Biomarker-Based, Open-Enrollment, Currently Recruiting Neurology
Clinical Trials by Phase and Indication, September 2009
- 4. Biomarker-Based, Open-Enrollment, Not Currently Recruiting Neurology
Clinical Trials by Phase and Indication, September 2009
- 5. Amyloid Plaques and Neurofi brillary Tangles in Alzheimer' s Disease
- 6. Rate of Dopaminergic Neuron Loss over the Course of Parkinson' s Disease
- 7. Number of Neurology Biomarker and Diagnostic Deals, 2004-First Half 2009
- 8. Neurology Deals: Biomarkers vs. Diagnostics, 2004-First Half 2009
- 9. Number of Neurology Biomarker and Diagnostic Deals, by Deal Focus,
2004-First Half 2009
- 10. Number of Neurology Biomarker and Diagnostic Deals, by Indication,
2004-First Half 2009
- 11. Companies with the Most Neurology Biomarker and Diagnostic Deals,
2004-First Half of 2009
- 12. Number of Neurology Biomarker and Diagnostic Deals, by Company Type,
2004-First Half 2009
|
 |
